Navigation Links
GlaxoSmithKline and the University of Edinburgh Agree to Collaborative Partnership for Drug Discovery
Date:10/26/2011

r. Diane Harbison, Head of Business Development at Edinburgh BioQuarter, said: "This collaborative partnership with a world-leader in drug discovery demonstrates the strength and depth of research being conducted here in Edinburgh. We are delighted to have been selected as one of just ten DPAc projects being awarded globally by GlaxoSmithKline."

About Edinburgh BioQuarter

At the heart of Scottish life sciences, Edinburgh BioQuarter is a joint venture between Alexandria Real Estate Equities, Inc, the NHS, the University of Edinburgh and Scottish Enterprise. Edinburgh BioQuarter commercializes world-leading medical research and brings investors, ideas and companies together at the BioQuarter campus on the outskirts of Edinburgh. For more information, visit www.edinburghbioquarter.com.


'/>"/>
SOURCE Edinburgh BioQuarter
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Ian Tomlinson Joins SBC Board as GlaxoSmithKline Representative Director
2. Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment
3. Isis Initiates Phase 1 Study of ISIS-TTRRx and Earns $5 Million Milestone Payment From GlaxoSmithKline
4. GlaxoSmithKline and Amplimmune Form Global Strategic Collaboration
5. FDA Advisory Committee Makes Favorable Recommendation for Cervarix, GlaxoSmithKlines Candidate Cervical Cancer Vaccine
6. Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)
7. GlaxoSmithKline Completes Acquisition of Stiefel
8. GlaxoSmithKline and Stiefel to Create New World-Leading Specialist Dermatology Business
9. Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD
10. Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes
11. GlaxoSmithKline Reports Q4 and Year End Results 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... May 22, 2013 Industry leaders ... VA for the Oak Ridge National Laboratory’s ... take place at the Hilton Alexandria Mark Center. ... Technologies 2013 conference on June 18 - ... , AdSave, American Elements, Applied Research Associates, ARA, ...
(Date:5/22/2013)... 2013 The Conference Forum ... to Advance Clinical Trials conference taking place on September ... MA. , Disruptive thinkers from Novartis, Pfizer, Eli ... bold approaches to reduce expensive infrastructure, engage patients and ... to be big, or novel, or it must change ...
(Date:5/22/2013)... May 22, 2013  Superior Controls, Inc. has ... by Business NH Magazine.  For the past 22 ... that distinguish themselves with extraordinary business and civic ... receive this honor," said Rick Pierro ... any recognition, this award is a reflection of ...
(Date:5/22/2013)... , May 22, 2013  Cleveland BioLabs, Inc. (NASDAQ: ... at the Second Annual Marcum LLP Microcap Conference, May 30, ... Neil Lyons , CPA, Chief Financial ... biodefense programs on May 30 at 1:30 p.m. Eastern Time.  ... be available on the Investors page of the Cleveland BioLabs ...
Breaking Biology Technology:Biodetection Technologies 2013 and Oak Ridge National Lab’s Biosurveillance Symposium to Bring Together Leading Organizations in Alexandria, VA from June 17-19, 2013 2Biodetection Technologies 2013 and Oak Ridge National Lab’s Biosurveillance Symposium to Bring Together Leading Organizations in Alexandria, VA from June 17-19, 2013 3Biodetection Technologies 2013 and Oak Ridge National Lab’s Biosurveillance Symposium to Bring Together Leading Organizations in Alexandria, VA from June 17-19, 2013 4Biodetection Technologies 2013 and Oak Ridge National Lab’s Biosurveillance Symposium to Bring Together Leading Organizations in Alexandria, VA from June 17-19, 2013 5Disruptive Innovation Hits Clinical Trials, Dedicated Event Launches 2Superior Controls of Seabrook, NH named Business of the Year for 2013 by Business NH Magazine 2Cleveland BioLabs to Present at Second Annual Marcum LLP Microcap Conference 2
... XEN-D0103, a potent and selective Kv1.5 antagonist, is safe ... LTD, the Cambridge-based biopharmaceutical company specialising in the discovery ... today from a phase 1 trial of XEN-D0103 administered ... potassium channel Kv1.5, was well tolerated and demonstrated good ...
... SAN DIEGO, March 19, 2012   Organovo Holdings, Inc. ... of an oversubscribed $15.2 million private placement. At the ... million through the sale of 6.9 million Units, at ... Post-closing Organovo has approximately 43.7 million shares of common ...
... such tests on samples sent in from all over Spain. ... truly personalised medicine. And researchers are exploring new ways to ... scale: the genes that are being read or transcribed; the ... the length of the telomeres capping its chromosomes. The ...
Cached Biology Technology:Xention Reports Positive Phase 1 Data for New Atrial Fibrillation Drug 2Xention Reports Positive Phase 1 Data for New Atrial Fibrillation Drug 3Organovo Announces Close of $15.2 Million Private Placement to Advance 3D Bioprinting for Medical Applications 2Organovo Announces Close of $15.2 Million Private Placement to Advance 3D Bioprinting for Medical Applications 3CNIO researchers take part in the most comprehensive personalized medicine study performed to date 2CNIO researchers take part in the most comprehensive personalized medicine study performed to date 3
(Date:5/22/2013)... join together in a major new effort to educate ... providing Earth,s people with clean water that looms ahead ... comment article in the current edition of Chemical ... American Chemical Society (ACS), the world,s largest scientific society. ... and Jerald L. Schnoor, Ph.D., explain that shortages of ...
(Date:5/22/2013)... Adventitious changes in cellular DNA can endanger the whole ... cancer. Researchers at Ludwig-Maximilians-Universitaet (LMU) in Munich now report ... the double helix. , The DNA in our cells ... in our bodies. The instructions for this are encoded ... in DNA, the bases adenine (A), cytosine (C), guanine ...
(Date:5/22/2013)... pollinating insects and wild plants have slowed in recent ... by the University of Leeds and the Naturalis Biodiversity ... reductions in the diversity of species in Britain, Belgium ... But the picture brightened markedly after 1990, with a ... hoverflies and wild plants. , Professor Bill ...
Breaking Biology News(10 mins):DNA damage: The dark side of respiration 2Encouraging signs for bee biodiversity 2Encouraging signs for bee biodiversity 3
... helped produce a new archaeological tool which could answer ... curve, which extends back 50,000 years is a major ... and geoscientists to establish the age of carbon-based materials. ... of climate change on human adaption and migrations. ...
... WALNUT CREEK, CAAs the U.S. Department of Energy ... energy, perennial grasses have emerged as major candidates for ... little is known about the specific biological traits of ... energy production, in part because such grasses typically have ...
... make some hearts flutter on Valentine,s Day, but in ... designed to do just the opposite. , The nanoparticles ... created in the laboratory of SUNY Distinguished Professor and ... who developed the lithium/silver vanadium oxide battery. The battery ...
Cached Biology News:Queen's helps produce archaeological 'time machine' 2First wild grass species and model system for energy crops sequenced 2First wild grass species and model system for energy crops sequenced 3Silver nanoparticles may one day be key to devices that keep hearts beating strong and steady 2